In vitro

Navigating through Maze of In-Vitro Diagnostics (IVD) Regulations: A Systematic Approach from Regulatory Strategy to Regulatory Approvals in U.S./Europe/Canada (September 16-17, 2021) - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021
Medical devices, Health, IVD, Regulation (EU) 2017/746, In vitro, Science

The "Navigating through Maze of In-vitro Diagnostics (IVD) Regulations: A systematic approach from Regulatory Strategy to Regulatory Approvals in U.S./Europe/Canada" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Navigating through Maze of In-vitro Diagnostics (IVD) Regulations: A systematic approach from Regulatory Strategy to Regulatory Approvals in U.S./Europe/Canada" training has been added to ResearchAndMarkets.com's offering.
  • In-vitro Diagnostics (IVD) products provide critical information on patient's health condition, based on which the healthcare provider develops and administers treatment plan.
  • This 2-day interactive course on in-vitro diagnostics is structured to understand the different set of IVD regulations, how to navigate through this maze of IVD regulations, and to win regulatory approvals.
  • This In-vitro Diagnostics (IVD ) course will make the attendees understand the IVD regulations and develop regulatory strategies that secure regulatory approvals.

Ortho Clinical Diagnostics to Report Second Quarter 2021 Results on August 4, 2021

Retrieved on: 
Friday, July 23, 2021
Medical tests, Ortho Clinical Diagnostics, Ortho, IVD, In vitro, Medicine, Biology, Natural sciences

RARITAN, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the worlds largest pure-play in vitro diagnostics companies, today announced it will report results for its second quarter 2021 ended July 4, 2021, after the market close on Wednesday, August 4, 2021.

Key Points: 
  • RARITAN, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the worlds largest pure-play in vitro diagnostics companies, today announced it will report results for its second quarter 2021 ended July 4, 2021, after the market close on Wednesday, August 4, 2021.
  • Ortho Clinical Diagnostics will hold a conference call the same day at 5:00 pm ET to discuss the results.
  • Interested parties can access the call and accompanying presentation on the Investors portion of the Companys website at https://ir.orthoclinicaldiagnostics.com/ .
  • Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the worlds largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.

Congenica Receives CE Mark for Genomic Analysis Software

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Emerging technologies, Biomarkers, Chemical pathology, Personalized medicine, Medical device, In vitro, Molecular diagnostics

Cambridge, United Kingdom 21 July 2021 - Congenica , the digital health company enabling rapid and accurate analysis of complex genomic data to transform peoples lives, today announces that its genomic interpretation software is now CE marked under the In Vitro Diagnostics Directive (98/79/EC).

Key Points: 
  • Cambridge, United Kingdom 21 July 2021 - Congenica , the digital health company enabling rapid and accurate analysis of complex genomic data to transform peoples lives, today announces that its genomic interpretation software is now CE marked under the In Vitro Diagnostics Directive (98/79/EC).
  • Medical devices require the CE mark designation for use in clinical applications in several key territories including the UK and the EU.
  • Congenicas world-leading genomic analysis technology platform supports the delivery of personalised medicine at scale, enabling rapid and accurate diagnoses for patients.
  • Congenicas world-leading software enables rapid genomic data analysis at scale and is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive.

Congenica Receives CE Mark for Genomic Analysis Software

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Emerging technologies, Biomarkers, Chemical pathology, Personalized medicine, Medical device, In vitro, Molecular diagnostics

Congenica Receives CE Mark for Genomic Analysis Software

Key Points: 
  • Cambridge, United Kingdom 21 July 2021 - Congenica , the digital health company enabling rapid and accurate analysis of complex genomic data to transform peoples lives, today announces that its genomic interpretation software is now CE marked under the In Vitro Diagnostics Directive (98/79/EC).
  • Medical devices require the CE mark designation for use in clinical applications in several key territories including the UK and the EU.
  • Congenicas world-leading genomic analysis technology platform supports the delivery of personalised medicine at scale, enabling rapid and accurate diagnoses for patients.
  • Congenicas world-leading software enables rapid genomic data analysis at scale and is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive.

Global EGFR Tests (In Vitro Diagnostics) Market Analysis and Forecast Model 2021 with COVID-19 Market Impact - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021
Health, General Health, Branches of biology, Laboratory techniques, Biology, Epidermal growth factor receptor, Oncogenes, Immunohistochemistry, EGFR, In vitro

The "EGFR Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "EGFR Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com's offering.
  • EGFR Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
  • The model discusses in detail the impact of COVID-19 on EGFR Tests market for the year 2020 and beyond.
  • The model includes EGFR Immunohistochemistry Tests, EGFR Sanger Sequencing Tests, EGFR Nucleic Acid Amplification Tests (NAATs), and EGFR Other Tests (EGFR ISH and Mass Array tests).

NanoDx™ Announces Licensing Collaboration with IBM Research for the Design and Manufacturing of Nanoscale Sensors for Rapid Diagnostic Testing

Retrieved on: 
Wednesday, July 14, 2021
Nanomedicine, Nanosensor, Nanotechnology, Science and technology, Food and Drug Administration, In vitro, Medical research, Technology

NanoDx is pursuing an Emergency Use Authorization from the U.S. FDA for rapid, two-minute, point-of-care COVID-19 testing.

Key Points: 
  • NanoDx is pursuing an Emergency Use Authorization from the U.S. FDA for rapid, two-minute, point-of-care COVID-19 testing.
  • "The field of diagnostics has changed rapidly during the past year with the emergence of COVID-19," said Sharad Joshi, President and Chief Executive Officer of NanoDx.
  • The company has built an extensive intellectual property portfolio around its nanosensor design and manufacturing processes that encompasses the entire field of in vitro diagnostics.
  • The integration of this technology design with NanoDx's highly-advanced nanosensor platform can help accelerate the ability to bring an extensive array of diagnostic solutions to market."

United States In Vitro Diagnostics Market Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 1, 2021
Biotechnology, Health, Medical devices, Alternatives to animal testing, In vitro, IVD, Medical tests, Companies, Science, DiaSorin, Natural sciences, Cepheid

The "United States In Vitro Diagnostics Market, Impact of COVID-19, Industry Trends, Growth, Opportunity Company Overview, Sales Analysis, Forecast" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States In Vitro Diagnostics Market, Impact of COVID-19, Industry Trends, Growth, Opportunity Company Overview, Sales Analysis, Forecast" report has been added to ResearchAndMarkets.com's offering.
  • In the United States, the growing prevalence of chronic and infectious diseases has spurred the development of the in-vitro diagnostics (IVD) market.
  • Besides, the United States In-Vitro Diagnostic market is broad and has various types of diagnostics instruments to perform different techniques.
  • In the United States, the In-vitro diagnostics market is currently in the South of the country, followed by the West being second.

BetterLife Secures Mitacs Funding in Collaboration with Carleton University Research Team for TD-0148A Preclinical Depression Studies

Retrieved on: 
Thursday, June 24, 2021
Higher education in Canada, MITACS, MITACS, In vitro, Science, Education

As part of the Accelerate Program funded by Mitacs, Dr. Argel Aguilar-Valles team will work with BetterLife to test TD-0148A in both in vitro and in vivo models that are established in their lab.

Key Points: 
  • As part of the Accelerate Program funded by Mitacs, Dr. Argel Aguilar-Valles team will work with BetterLife to test TD-0148A in both in vitro and in vivo models that are established in their lab.
  • Dr. Argel Aguilar-Valles said, We are delighted to have Mitacs support to examine BetterLifes TD-0148A in our established animal depression models.
  • Carleton Neuroscience has an international reputation for research on stress and its effects on brain functioning and mental health.
  • Mitacs is a not-for-profit organization that fosters growth and innovation in Canada by solving business challenges with research solutions from academic institutions.

Europe In-Vitro Diagnostics Market Forecast Report 2021-2027: Increasing Adoption and Popularity of Automation in Clinical Laboratories - ResearchAndMarkets.com

Retrieved on: 
Monday, June 21, 2021
Health, Biotechnology, Alternatives to animal testing, In vitro, Natural sciences, Life sciences, Medical tests, Science

The in-vitro diagnostics market has accounted for a significant market share in the healthcare industry during the COVID-19 pandemic.

Key Points: 
  • The in-vitro diagnostics market has accounted for a significant market share in the healthcare industry during the COVID-19 pandemic.
  • Thus, such instances are significantly driving the Europe in-vitro diagnostics market and it is expected to continue in the following years.
  • The Europe in-vitro diagnostics market is segmented on the basis of product and services, technology, application, and end user.
  • Therefore, these countries have significantly contributed to the growth of the Europe in-vitro diagnostics market.

InSphero and Pharmaceutical Companies Form Pre-Competitive Consortium to Advance Development of In Vitro Tools to Screen and Predict Drug-Induced Liver Injury (DILI)

Retrieved on: 
Wednesday, June 16, 2021
Biotechnology, General Health, Health, Stem cells, Pharmaceutical, Alternatives to animal testing, In vitro, In vivo, Animal disease model, Science, Biology, Natural sciences

The consortium will evaluate methods for recapitulating DILI-specific effects observed in animal models and patients using in vitro human and animal liver spheroid models and a DILI compound library.

Key Points: 
  • The consortium will evaluate methods for recapitulating DILI-specific effects observed in animal models and patients using in vitro human and animal liver spheroid models and a DILI compound library.
  • We intend to use 3D liver microtissues from animals and humans to evaluate DILI mechanisms leading to observed in vivo effects.
  • Each participating pharma member will provide a set of DILI compounds for 3D in vitro mechanistic investigations conducted by InSphero.
  • Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro.